Clinical Trial Update: A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates how different fasting durations and withholding dulaglutide affect gastric retention in participants with Type 2 diabetes mellitus.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dulaglutide (dulaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Status: ACTIVE_NOT_RECRUITING